INTRODUCTION

Globally, coronary heart disease (CHD) remains the leading cause of morbidity and mortality.\(^1\) Atherosclerosis has been regarded as the main underlying mechanism of CHD. The classical doctrine indicates that atherosclerosis is a chronic inflammatory condition characterized by an inflammatory response of the arterial wall (generally speaking, including the tunica intima, media and adventitia) to injuries promoted by risk factors such as obesity, type 2 diabetes mellitus (T2DM) and so on.\(^2\) It was suggested that low-grade inflammation stress might contribute to the pathogenesis of atherosclerosis.\(^3\) More recently, accumulated compelling evidence has delineated the indispensable roles of perivascular adipose tissue in the pathogenesis of atherosclerosis.\(^4\) In brief, perivascular adipose tissue lying on the outside of adventitia without laminar structures or any organized barrier to separate them\(^5\) might affect the development of atherosclerosis by releasing pro-inflammatory adipokines (e.g., leptin and resistin) and anti-inflammatory adipokines (e.g., adiponectin).\(^11\)

Secreted frizzled-related protein 5 (SFRP5), an anti-inflammatory adipokine secreted by adipocytes, has been demonstrated to exert its anti-inflammatory effect via antagonizing the non-canonical wingless-type family member 5A (WNT5A) signalling pathways. The WNT5A protein, as a potent pro-inflammatory signalling molecule, is strongly involved in a variety of inflammatory disorders such as obesity, type 2 diabetes mellitus (T2DM) and atherosclerosis. In this review, we systematically outlined the current understanding on the roles of SFRP5 in the pathogenesis of three inflammatory diseases including obesity, T2DM and coronary heart disease (CHD). Our review might stimulate future research using SFRP5 as a promising novel therapeutic target for the treatment of obesity, T2DM and CHD.

KEYWORDS
adipokine, anti-inflammatory, coronary heart disease, obesity, SFRP5, type 2 diabetes mellitus, WNT5A
and myocardial inflammation secondary to ischaemia/reperfusion injury\textsuperscript{32} or transverse aortic constriction.\textsuperscript{33} As an endogenous inhibitor of WNT5A signalling pathways, SFRP5 has been suggested to play vital roles in obesity,\textsuperscript{12} T2DM\textsuperscript{12} and CHD.\textsuperscript{34}

Given obesity and T2DM have been well recognized as two major risk factors of CHD, there must be several inflammatory mediators linking obesity, T2DM to CHD. However, as a novel anti-inflammatory adipokine, it remains unclear whether SFRP5 could be a member of these inflammatory mediators. This review summarizes the roles of SFRP5 in these three inflammatory disorders, respectively. Furthermore, we discussed how SFRP5 may represent a novel link between obesity, T2DM and CHD.

### 2 | ROLES OF SFRP5 IN OBESITY

As a public health issue, obesity, which is characterized by excess of body fat, especially excessive visceral adipose tissue accumulation, is a multifactorial disorder, involving genetics, hormones, diets and environments, and is considered as a state in which chronic low-grade inflammation occurs within adipose tissue.\textsuperscript{35} Ouchi et al.\textsuperscript{12} have observed that in leptin-deficient (ob/ob) mice, Zucker diabetic fatty mice and wild-type mice fed a high-fat, high-sucrose diet for 24 weeks, obesity contributed to lower levels of SFRP5 expression, higher levels of WNT5A expression and an increase in the ratio of pro-inflammatory WNT5A to anti-inflammatory SFRP5. They also measured SFRP5

![Diagram of SFRP5 at the crossroad between obesity, T2DM and CHD](image-url)

**Figure 1** SFRP5 at the crossroad between obesity, T2DM and CHD. As a member of the non-canonical WNT family of proteins, WNT5A mainly activates WNT5A/Ca\textsuperscript{2+} and WNT5A/JNK signalling pathways. One branch of the non-canonical signalling pathways involves the activation of small GTPases Rho and Rac. After WNT5A binds to FzR, activated DSH integrates Rho and Rac into it, respectively. Then, the DSH-Rho and DSH-Rac complexes activate JNK to regulate the PCP pathway. In addition, WNT5A can also bind to Ror2 to directly activate JNK to mediate the PCP pathway. This signalling branch has been shown to regulate cell orientation. Another branch, when activated, leads to PLC-mediated increase in intracellular Ca\textsuperscript{2+} levels, which further activates CAMKII and PKC. This signalling branch has been demonstrated to mediate cell proliferation, migration and adhesion. Inflammation plays an important role in this process, which is from obesity, IR and ED to atherosclerosis. As we know, CHD has been regarded as an atherosclerosis-related disease and the development of T2DM is significantly correlated with insulin resistance. Therefore, we propose that SFRP5, as an anti-inflammatory adipokine, might link obesity, T2DM to CHD. Abbreviations: AS, atherosclerosis; CAMKII, Ca\textsuperscript{2+}/calmodulin-dependent protein kinase II; CD, cytoplasmic domain; CHD, coronary heart disease; CRD, cysteine-rich domain; DSH, dishevelled; EC, endothelial cell; ED, endothelial dysfunction; FzR, Frizzled receptor; IR, insulin resistance; JNK, C-jun N-terminal kinase; Mac, macrophage; NTR, netrin-like domain; PCP, planar cell polarity; PKC, protein kinase C; PLC, phospholipase C; Ror2, receptor tyrosine kinase-like orphan receptor 2; SFRP5, secreted frizzled-related protein 5; SMC, smooth muscle cell; T2DM, type 2 diabetes mellitus; WNT5A, wingless-type family member 5A
expression in visceral fat biopsy specimens of obese patients and found that patients with adipose tissue inflammation showed a decrease in SFRP5 transcript expression compared with obese patients without adipose tissue inflammation. These results suggested that regulation of SFRP5 expression is related to obesity.

Recently, multiple clinical studies demonstrated the relationship between anti-inflammatory SFRP5 and obesity (Table 1). Hu ZP et al36 found that circulating plasma levels of SFRP5 were drastically diminished in Chinese obese patients compared with patients with normal bodyweight and plasma SFRP5 concentrations were negatively correlated with body fat parameters, such as body mass index, waist circumference and the waist-to-hip ratio. In line with this study, Tan et al37 observed that circulating SFRP5 concentrations were significantly lower in obese children, especially in those with metabolic syndrome, and negatively correlated with markers of adiposity, including body mass index and waist circumference. Interestingly, lifestyle intervention gave rise to significant weight loss and up-regulated SFRP5 expression. Moreover, another clinical study conducted by Hu WJ et al38 found that overweight/obese patients had significantly lower SFRP5 levels than lean counterparts, and plasma SFRP5 concentrations were negatively correlated with anthropometric variables, including body mass index, the waist-to-hip ratio and per cent body fat. Recently, Akoumianakis et al39 demonstrated that circulating WNT5A concentrations were significantly increased in obese patients, accompanied by reduced plasma levels of its antagonist SFRP5. They also found a strong positive association between circulating WNT5A/SFRP5 ratio and body mass index. However, Schulte et al40 observed that both circulating serum WNT5a concentrations and circulating serum levels of SFRP5 were elevated in obese patients compared with lean patients. Additionally, Schulte et al40 displayed that caloric restriction beneficially increased serum concentrations of anti-inflammatory SFRP5 in obese patients, while pro-inflammatory WNT5A levels were not significantly decreased. In contrast, Catalan et al41 demonstrated that serum concentrations of WNT5A were decreased in response to surgically induced weight loss, whereas anti-inflammatory SFRP5 level was not significantly altered. These findings provided a novel regulatory system of chronic low-grade inflammation in obesity, which could be affected by nutritional intervention or weight loss.

As mentioned above, pro-inflammatory WNT5A and anti-inflammatory SFRP5 both play pivotal roles in the development of obesity. Therefore, we propose that SFRP5 may exert a protective role in the pathogenesis of adipose tissue inflammation and obesity via non-canonical WNT5A signalling pathway. Importantly, the specific mechanisms remain to be elucidated through a series of basic studies.

### 3 | SFRP5 IN THE PATHOGENESIS OF T2DM

Insulin resistance has been identified as one of the important characteristics of T2DM and also been considered as an indispensable factor underlying the pathogenesis of T2DM, which usually precedes the onset of this disease.42 It has been demonstrated that the development of insulin resistance is linked to a macrophage-mediated inflammation of adipose tissue and is associated with chronic low-grade inflammation.43-45 Therefore, it is boldly speculated that SFRP5, which is a novel anti-inflammatory adipokine and also an endogenous inhibitor of WNT5A signalling pathways, might prevent macrophage-mediated inflammation of adipose tissue by antagonizing the WNT5A protein to improve the insulin sensitivity, consequently playing a protective role in the pathogenesis of T2DM. Intriguingly, a study conducted by Ouchi et al12 was consistent with this hypothesis. They observed that SFRP5-deficient (SFRP5−/−) mice fed a high-fat diet showed greater adipose tissue inflammation mediated by macrophage and insulin resistance compared with wild-type mice due to unrestrained WNT5A activity. On the contrary, two weeks after intravenously administered Ad-SFRP5, insulin sensitivity was significantly improved. Interestingly, in vitro, up-regulation of SFRP5 expression in 3T3-L1 adipocytes prevented the inflammatory, insulin-resistant state by blocking WNT5A activity. Similarly, Lv et al47 found that overexpression and over-secretion of SFRP5 in

---

**TABLE 1** Clinical studies concerning SFRP5 and WNT5A in obesity, T2DM and CHD

| Disorders | SFRP5 | WNT5A | IR | References |
|-----------|-------|-------|----|-----------|
| Obesity   | ↓↓↓   | /     | (−) | Hu ZP et al36 |
| ↓↓↓       | ↑↑↑a  | (−)   | Tan et al37 |
| ↓↑↑       | /     | (−)   | Hu WJ et al38 |
| ↑↑↑a      | ↑↑↑   | /     | Schulte et al40 |
| ↓↓↓a      | ↑↑↑   | /     | Catalan et al41 |
| ↓↓↓       | ↑↑↑   | /     | Akoumianakis et al39 |
| T2DM      | ↓↓↓   | /     | (−) | Hu ZP et al36 |
| ↓↓↓       | /     | (−)   | Hu WJ et al38 |
| ↓↓↓       | /     | (−)   | Cheng et al38 |
| ↓↓↓       | /     | (−)   | Carstensen-Kirberg et al39 |
| ↑↑↑       | /     | None  | Caniell et al50 |
| ↑↑↑       | ↓↓↓   | None  | Lu et al51 |
| CHD       | ↓↓↓   | /     | (−) | Miyoshi et al34 |
| ↓↓↓       | ↑↑↑   | /     | Akoumianakis et al39 |
| STEMI     | ↑↑↑   | /     | (−) | Du et al55 |

Note: ↑↑↑ indicates that the SFRP5 levels or WNT5A levels were increased in patients with obesity, T2DM and CHD compared with healthy controls, respectively. ↓↓↓ indicates that the SFRP5 levels or WNT5A levels were decreased in patients with obesity, T2DM and CHD compared with healthy controls, respectively. (−) indicates that the SFRP5 levels were negatively correlated with IR. None indicates that there were no relationships between the SFRP5 levels and IR. / indicates that the data were not mentioned in this study.

Abbreviations: CHD, coronary heart disease; IR, insulin resistance; SFRP5, secreted frizzled-related protein 5; STEMI, ST-segment elevation myocardial infarction; T2DM, type 2 diabetes mellitus; WNT5A, wingless-type family member 5A.

aIndicates that there was no statistical significance.
3T3-L1 adipocytes may be one key mechanism by which rosiglitazone and metformin improve insulin sensitivity.

Additionally, multiple human studies have demonstrated that SFRP5 plays a role in the pathogenesis of T2DM (Table 1). Hu ZP et al. found that circulating plasma concentrations of SFRP5 were decreased in T2DM patients compared with healthy controls and they were negatively correlated with homeostasis model assessment of insulin resistance, suggesting that SFRP5 might exert a protective effect on the mechanism of T2DM. Similar results were observed by clinical studies conducted by Hu WJ et al., Cheng et al. and Carstensen-Kirberg et al., and all indicated a possible role for SFRP5 as a protective factor in the pathogenesis of T2DM. In contrast, Canivell et al. observed that circulating plasma levels of SFRP5 were augmented in patients with T2DM compared with pre-diabetic patients and healthy controls. These findings are consistent with another study conducted by Lu et. al. who found that circulating plasma SFRP5 concentrations were also elevated but circulating plasma levels of WNT5A were diminished in T2DM patients compared with non-diabetic patients. However, there were no relationships between circulating plasma SFRP5 levels and insulin resistance based on results from these two studies.

Collectively, although the protective roles of SFRP5 in the pathogenesis of T2DM have been explored both in animal and cell studies, controversial results were found in clinical studies. Thus, the relationships between SFRP5 and T2DM in human remain to be explored. Therefore, further well-designed studies with larger sample size and more ethnic groups with respect to the roles of SFRP5 in the pathogenesis of T2DM should urgently be considered.

4 | SFRP5 CONTRIBUTING TO CHD

Atherosclerosis is the basic pathological foundation of CHD. Multiple mechanisms are linked to the pathogenesis of atherosclerosis, including endothelial dysfunction, which is characterized by an imbalance between endothelium-dependent vasorelaxation and vasoconstriction, the migration and proliferation of vascular smooth muscle cells, Breton-Romero et al. observed that in aortic endothelial cells derived from patients with T2DM, WNT5A induced impairment of endothelial nitric oxide synthase activation and nitric oxide production was reversed by WNT5A and JNK inhibition (Box5 and SP600125). Interestingly, a recent study published in Arteriosclerosis, thrombosis and vascular biology provided the first direct evidence that SFRP5 exerted its restorative effect on the WNT5A-induced endothelial dysfunction through the inhibition of the WNT5A/JNK pathway and the up-regulation of endothelial nitric oxide production, which suggests a possible role of SFRP5 as a protective factor in the development atherosclerosis under conditions of metabolic dysfunction. Similarly, Akoumianakis et al. demonstrated that WNT5A could increase vascular oxidative stress and reduce nitric oxide bioavailability in human vessels, which can be restored by SFRP5. Intriguingly, they also observed that WNT5A increased the migration of human vascular smooth muscle cells without affecting their proliferation, an effect reversed by SFRP5. These findings identified SFRP5/WNT5A signalling pathway as a link between obesity and atherosclerosis. Furthermore, Nakamura et al. found that compared with wild-type C57BL/6 mice, SFRP5−/− mice showed larger infarct sizes, greater infiltration of WNT5A-positive macrophages and inflammatory cytokine and chemokine gene expression in the ischaemic lesions, increased cardiomyocytes apoptosis and decreased cardiac function following ischaemia/reperfusion injury. And in vitro, the WNT5A protein promoted JNK activation and augmented inflammatory gene expression in bone marrow-derived macrophages, while treatment with SFRP5 could inhibit these effects. From these findings, we can conclude that SFRP5, as a cardioprotective adipokine, could attenuate cardiac inflammation and protect the heart from ischaemia/reperfusion injury possibly via WNT5A/JNK signalling pathway.

As for clinical studies (Table 1), Miyoshi et al. carried out one clinical study including 185 patients, who were divided into CHD group and non-CHD group and circulating serum concentrations of SFRP5 were measured. And these investigators for the first time observed that lower serum levels of SFRP5 were significantly related to CHD and the severity of CHD was negatively associated with serum SFRP5 levels, suggesting the link between SFRP5 levels and CHD. But to our regret, they did not measure circulating serum WNT5A levels. Fortunately, a case-control study conducted by Akoumianakis et al. complemented this work. They found that patients with CHD had higher circulating WNT5A levels, lower circulating SFRP5 levels and a circulating plasma WNT5A/SFRP5 ratio compared with patients without CHD. And the presence of CHD was associated with plasma WNT5A (positive) concentrations, plasma SFRP5 (negative) concentrations and plasma WNT5A/SFRP5 ratio (positive) independently of traditional risk factors (hypertension, hyperlipidemia, diabetes and smoking). Interestingly, they observed that circulating WNT5A levels were independently-associated with calcified coronary plaque progression and new-onset coronary calcification. This promising result further highlighted the role of SFRP5 and WNT5A in CHD. Besides, SFRP5 may be a promising therapeutic target in acute ST-segment elevation myocardial infarction (STEMI). Recent study conducted by Du et al. found that serum SFRP5 levels were significantly increased during the early phase of acute STEMI but attenuated over time. Interestingly, high serum SFRP5 levels were significantly correlated with improving cardiac function at an early phase (3 months) after primary percutaneous coronary intervention. Similarly, the serum WNT5A levels were not measured.

However, to date, human studies showing the relationships between SFRP5 and CHD are still scanty and direct roles of SFRP5 in the pathogenesis of atherosclerosis and myocardial infarction hitherto remain obscure. Thus, more clinical and basic studies should be performed urgently.

5 | SFRP5 AT THE CROSSROAD BETWEEN OBESITY, T2DM AND CHD

There are multiple papers focusing on the crucial roles of adipokines in constituting a critical link between the obesity, T2DM and atherosclerosis or cardiovascular diseases. SFRP5, as a novel
anti-inflammatory adipokine, might be at the crossroad between obesity, T2DM and CHD (Figure 1). It is known that obesity, especially the central obesity, mainly participates in the formation and development of insulin resistance by affecting the sensitivity of insulin. Moreover, it has been demonstrated that improving endothelial function could ameliorate insulin resistance, whereas improving insulin sensitivity could ameliorate endothelial dysfunction, which suggesting the reciprocal relationships between insulin resistance and endothelial dysfunction.58 Endothelial dysfunction has been identified as the primary and a crucial step of the development of atherosclerosis.52,59,60 In addition, inflammation plays an important role in this process, which is also the common disease feature of obesity, insulin resistance and endothelial dysfunction. Therefore, we propose that SFRP5, as an anti-inflammatory adipokine, might link obesity, T2DM to CHD.

6 | CONCLUSIONS AND PERSPECTIVES

In this review, we summarized the indispensable roles of SFRP5, a novel anti-inflammatory adipokine, in the pathogenesis of these three inflammatory disorders, namely obesity, T2DM and CHD. Taken together, we propose that SFRP5 binds to WNT5A and blocks the non-canonical WNT5A signalling pathways, consequently reducing chronic inflammation and exerting its protective effect on reducing/retarding obesity, insulin resistance and atherosclerosis. SFRP5, as an anti-inflammatory adipokine, might link obesity, T2DM-CHD. Thereby, this hypothesis might be of clinical relevance since SFRP5 can be a promising candidate for future treatments of these three inflammatory disorders. Despite ongoing and available research, further studies are required to investigate whether WNT5A non-canonical signalling pathways are the only one to participate in the development of these three inflammatory disorders or not. This is because WNT5A mainly acts on the non-canonical WNT5A signalling pathways; however, it can also activate the canonical β-catenin signalling pathway in virtue of the receptor availability.59 In summary, inflammation is the common disease feature of these three inflammatory disorders—obesity, T2DM and CHD, which makes it possible for SFRP5 to be at the crossroad between obesity, T2DM and CHD. Further exploration of the biological functions of SFRP5 may pave the way for it to serve as a potential novel treatment option for obesity, T2DM and CHD.

ACKNOWLEDGEMENTS

Our work was supported by 81670321, 81871105 and 81870270 from the National Natural Science Foundation of China (NSFC).

CONFLICT OF INTEREST

The authors confirm that there are no conflicts of interest.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Chengxing Shen https://orcid.org/0000-0002-3882-7586

REFERENCES

1. Benjamin EJ, Virani SS, Callaway CW, et al. Heart disease and stroke statistics-2018 update: a report from the American heart association. Circulation. 2018;137:e67-e492.
2. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340:115-126.
3. Shen CX, Chen HZ, Ge JB. The role of inflammatory stress in acute coronary syndrome. Chin Med J (Engl). 2004;117:133-139.
4. Ohman MK, Luo W, Wang H, et al. Perivascular visceral adipose tissue induces atherosclerosis in apolipoprotein E deficient mice. Atherosclerosis. 2011;219:33-39.
5. Verhagen SN, Visseren FL. Perivascular adipose tissue as a cause of atherosclerosis. Atherosclerosis. 2011;214:3-10.
6. Szasz T, Webb RC. Perivascular adipose tissue: more than just structural support. Clin Sci (Lond). 2012;122:1-12.
7. Chang L, Milton H, Eitzman DT, et al. Paradoxical roles of perivascular adipose tissue in atherosclerosis and hypertension. Circ J. 2013;77:11-18.
8. Brown NK, Zhou Z, Zhang J, et al. Perivascular adipose tissue in vascular function and disease: a review of current research and animal models. Arterioscler Thromb Vasc Biol. 2014;34:1621-1630.
9. Mancio J, Oikonomou EK, Antoniades C. Perivascular adipose tissue and coronary atherosclerosis. Heart. 2018;104:1654-1662.
10. Tanaka K, Sata M. Roles of perivascular adipose tissue in the pathogenesis of atherosclerosis. Front Physiol. 2018;9:3.
11. Mólca F, Morel S, Kwak BR, et al. Adipokines at the crossroad between obesity and cardiovascular disease. Thromb Haemost. 2015;113:553-566.
12. Ouchi N, Higuchi A, Ohashi K, et al. Sfrp5 is an anti-inflammatory adipokine that modulates metabolic dysfunction in obesity. Science. 2010;329:454-457.
13. Ehrlund A, Mejhert N, Lorente-Cebrian S, et al. Characterization of the Wnt inhibitors secreted frizzled-related proteins (SFRPs) in human adipose tissue. J Clin Endocrinol Metab. 2013;98:E503-E508.
14. Bhatt PM, Malgor R. Wnt5a: a player in the pathogenesis of atherosclerosis and other inflammatory disorders. Atherosclerosis. 2014;237:155-162.
15. Masckauchan TN, Agalli D, Vorontchikhina M, et al. Wnt5a signaling induces proliferation and survival of endothelial cells in vitro and expression of MMP-1 and Tie-2. Mol Biol Cell. 2006;17:5163-5172.
16. Cheng CW, Yeh JC, Fan TP, et al. Wnt5a-mediated non-canonical Wnt signalling regulates human endothelial cell proliferation and migration. Biochem Biophys Res Commun. 2008;365:285-290.
17. Breton-Romero R, Feng B, Holbrook M, et al. Endothelial dysfunction in human diabetes is mediated by Wnt5a-JNK signaling. Arterioscler Thromb Vasc Biol. 2016;36:561-569.
18. Cho YK, Kang YM, Lee SE, et al. Effect of SFRP5 (Secreted Frizzled-Related Protein 5) on the WNT5A (wingless-type family member 5A)-induced endothelial dysfunction and its relevance with arterial stiffness in human subjects. Arterioscler Thromb Vasc Biol. 2018;38:1358-1367.
19. Woldt E, Terrand J, Mihm M, et al. The nuclear hormone receptor PPARGamma counteracts vascular calcification by inhibiting Wnt5a signaling in vascular smooth muscle cells. Nat Commun. 2012;3:1077.
20. Zhang Y, Liu Z, Zhou M, et al. MicroRNA-129-5p inhibits vascular smooth muscle cell proliferation by targeting Wnt5a. Exp Ther Med. 2016;12:2651-2656.
21. Pereira C, Schara DJ, Bachl EB, et al. Wnt5a/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the anti-inflammatory action of activated protein C and interleukin-10. Arterioscler Thromb Vasc Biol. 2008;28:504-510.
22. Shao Y, Zheng Q, Wang W, et al. Biological functions of macrophage-derived Wnt5a, and its roles in human diseases. Oncotarget. 2016;7:67674-67684.
23. Sen M, Lauterbach K, El-Gabalawy H, et al. Expression and function of wingless and frizzled homologs in rheumatoid arthritis. *Proc Natl Acad Sci U S A*. 2000;97:2791-2796.

24. Blumenthal A, Ehlers S, Lauber J, et al. The wingless homolog WNT5A and its receptor frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation. *Blood*. 2006;108:965-973.

25. Romanowska M, Evans A, Kellock D, et al. Wnt5a exhibits layer-specific expression in adult skin, is upregulated in psoriasis, and synergizes with type I interferon. *PLoS ONE*. 2009;4:e5254.

26. Tang Q, Chen C, Zhang Y, et al. Wnt5a regulates the cell proliferation and adipogenesis via MAPK-independent pathway in early stage of obesity. *Cell Biol Int*. 2018;42:63-74.

27. Fuster JJ, Zuriaga MA, Ngo DT, et al. Noncanonical Wnt signaling promotes obesity-induced adipose tissue inflammation and metabolic dysfunction independent of adipose tissue expansion. *Diabetes*. 2015;64:1235-1248.

28. Mark A, Christman II, Goetz DJ, et al. Wnt5a is expressed in murine and human atherosclerotic lesions. *Am J Physiol Heart Circ Physiol*. 2008;294:H2864-H2870.

29. Bhatt PM, Lewis CJ, House DL, et al. Increased Wnt5a mRNA expression in advanced atherosclerotic lesions, and oxidized LDL treated human monocyte-derived macrophages. *Open Circ Vasc J*. 2012;5:1-7.

30. Malgor R, Bhatt PM, Connolly BA, et al. Wnt5a, TLR2 and TLR4 are elevated in human advanced atherosclerotic lesions. *Inflamm Res*. 2014;63:277-285.

31. Pashirzad M, Shafiee M, Rahmani F, et al. Role of Wnt5a in the pathogenesis of inflammatory diseases. *J Cell Physiol*. 2017;232:1611-1616.

32. Nakamura K, Sano S, Fuster JJ, et al. Secreted frizzled-related protein 5 diminishes cardiac inflammation and protects the heart from ischemia/reperfusion injury. *J Biol Chem*. 2016;291:2566-2575.

33. Wang Y, Sano S, Oshima K, et al. Wnt5a-mediated neutrophil recruitment has an obligatory role in pressure overload-induced cardiac dysfunction. *Circulation*. 2019;140:487-499.

34. Miyoshi T, Doi M, Usui S, et al. Low serum level of secreted frizzled-related protein 5, an anti-inflammatory adipokine, is associated with coronary artery disease. *Atherosclerosis*. 2014;233:454-9.

35. Lee H, Lee IS, Choue R. Obesity, inflammation and diet. *Pediatr Gastroenterol Hepatol Nutr*. 2013;16:143-152.

36. Hu Z, Deng H, Qu H. Plasma SFRPS levels are decreased in Chinese subjects with obesity and type 2 diabetes and negatively correlated with parameters of insulin resistance. *Diabetes Res Clin Pract*. 2013;99:391-395.

37. Tan X, Wang X, Chu H, et al. SFRPS correlates with obesity and metabolic syndrome and increases after weight loss in children. *Clin Endocrinol (Oxf)*. 2014;81:363-369.

38. Hu W, Li L, Yang M, et al. Circulating Sfrp5 is a signature of obesity-related metabolic disorders and is regulated by glucose and lira-glutide in humans. *J Clin Endocrinol Metab*. 2013;98:290-298.

39. Akoumianakis I, Sanna F, Margaritis M, et al. Adipose tissue-derived WNT5A regulates vascular redox signaling in obesity via USP17/RAC1-mediated activation of NADPH oxidases. *Sci Transl Med*. 2019;11.

40. Schulte DM, Muller N, Neumann K, et al. Pro-inflammatory wnt5a and anti-inflammatory sFRPS are differentially regulated by nutritional factors in obese human subjects. *PLoS ONE*. 2012;7:e32437.

41. Catalán V, Gomez-Ambrosi J, Rodriguez A, et al. Activation of non-canonical Wnt signaling through WNT5A in visceral adipose tissue of obese subjects is related to inflammation. *J Clin Endocrinol Metab*. 2014;99:E1407-E1417.

42. Xu L, Kitade H, Ni Y, et al. Roles of chemokines and chemokine receptors in obesity-associated insulin resistance and nonalcoholic fatty liver disease. *Biomolecules*. 2015;5:1563-1579.

43. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest*. 2003;112:1796-1808.

44. Hotamisligil GS. Inflammation and metabolic disorders. *Nature*. 2006;444:860-867.

45. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J Clin Invest*. 2003;112:1821-1830.

46. Wellen KE. Inflammation, stress, and diabetes. *J Clin Invest*. 2005;115:1111-1119.

47. Lu C, Jiang Y, Wang H, et al. Sfrp5 expression and secretion in adipocytes are up-regulated during differentiation and are negatively correlated with insulin resistance. *Cell Biol Int*. 2012;36:851-855.

48. Cheng L, Zhang D, Chen B. Declined plasma Sfrp5 concentration in patients with type 2 diabetes and latent autoimmune diabetes in adults. *Pak J Med Sci*. 2015;31:602-605.

49. Carstensen-Kirberg M, Kannenberg JM, Huth C, et al. Inverse associations between serum levels of secreted frizzled-related protein-5 (SFRP5) and multiple cardiometabolic risk factors: KORA F4 study. *Cardiovasc Diabetol*. 2017;16:109.

50. Caniwell S, Rebuffat S, Ruano EG, et al. Circulating SFRPS levels are elevated in drug-naive recently diagnosed type 2 diabetic patients as compared with prediabetic subjects and controls. *Diabetes Metab Res Rev*. 2015;31:212-219.

51. Lu YC, Wang CP, Hsu CC, et al. Circulating secreted frizzled-related protein 5 (Sfrp5) and wingless-type MMTV integration site family member 5a (Wnt5a) levels in patients with type 2 diabetes mellitus. *Diabetes Metab Res Rev*. 2013;29:551-556.

52. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. *Circulation*. 2004;109:II-27-II-32.

53. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. *Science*. 1973;180:1332-1339.

54. Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. *Circ Res*. 2016;118:692-702.

55. Du Y, Zhao Y, Zhu Y, et al. High serum secreted frizzled-related protein 5 levels associated with early improvement of cardiac function following ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. *J Atheroscler Thromb*. 2019;26:868-878.

56. Freitas Lima LC, Braga VDA, do Socorro de França Silva M, et al. Adipokines, diabetes and atherosclerosis: an inflammatory association. *Update on the association between SFRP5, an anti-inflammatory adipokine, and insulin resistance in obesity and type 2 diabetes mellitus*. *Diabetes Metab Res Rev*. 2015;31:602-605.

57. Paquot N, Tappy L. Adipocytokines: link between obesity, type 2 diabetes and atherosclerosis. *Rev Med Liege*. 2005;60:369-373.

58. Kim JA, Montagnani M, Koh KK, et al. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. *Circulation*. 2006;113:1888-1904.

59. Gimbrone Jr MA, Garcia-Cardena G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. *Circ Res*. 2005;96:620-636.

60. Wang D, Wang Z, Zhang L, et al. Roles of cells from the arterial vessel wall in atherosclerosis. *Mediators Inflamm*. 2017;2017:8135934.